Role of Endogenous GLP-1 and its Agonists in Osteopenia and Osteoporosis: But We Little Know Until Tried

ISSN: 1875-6417 (Online)
ISSN: 1573-3998 (Print)


Volume 10, 6 Issues, 2014


Download PDF Flyer




Current Diabetes Reviews

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Norman E. Cameron
University of Aberdeen
Aberdeen, Scotland
UK


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Role of Endogenous GLP-1 and its Agonists in Osteopenia and Osteoporosis: But We Little Know Until Tried

Author(s): Athanasia Papazafiropoulou, Nikolaos Papanas, Stavros Pappas and Efstratios Maltezos

Affiliation: Diabetes Centre, Third Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Greece.

Abstract

The present brief review looks at the evidence on the role of GLP-1 and its agonists in osteopenia and osteoporosis in type 2 diabetes (T2DM). There is accumulating data to suggest a favourable effect of GLP-1 on bone metabolism. However, most data is from experimental studies, while clinical confirmation is still inadequate. Moreover, little is known on the precise mechanisms underlying these effects. Therefore, we need randomised clinical trials in T2DM patients to learn more on the action of GLP-1 on bone metabolism and its potential clinical implications.

Keywords: Bone metabolism, fractures, GLP-1, incretins, type 2 diabetes mellitus.

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 10
Issue Number: 1
First Page: 43
Last Page: 47
Page Count: 5
DOI: 10.2174/1573399810666140217114848
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science